Investigational Drug Information for Buparlisib
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $100
Remove trial restrictions
What is the drug development status for Buparlisib?
Buparlisib is an investigational drug.
There have been 40 clinical trials for Buparlisib. The most recent clinical trial was a Phase 3 trial, which was initiated on October 3rd 2012.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
Summary for Buparlisib
|US Patent Applications||1,929|
|WIPO Patent Applications||1,429|
|Japanese Patent Applications||446|
|Clinical Trial Progress||Phase 3 (2012-10-03)|
Recent Clinical Trials for Buparlisib
|The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC||Adlai Nortye Biopharma Co., Ltd.||Phase 3|
|A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma||Janssen Scientific Affairs, LLC||Phase 1|
|A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma||Novartis Pharmaceuticals||Phase 1|
Clinical Trial Summary for Buparlisib
Top disease conditions for Buparlisib
Top clinical trial sponsors for Buparlisib
US Patents for Buparlisib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|